Calgary, Alberta (ots/PRNewswire) - The presentations at the ESC Congress symposium highlighted apabetalone and the opportunity and need for a novel approach to the treatment of high risk cardiovascular disease and diabetes. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Sunday, ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - - Xiidra is the only prescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease - Resources are available to support patients seeking information regarding coverage and savings offers - Xiidra is the first medication in a ...
Munich (ots/PRNewswire) - Sub-analysis data from atrial fibrillation patient registry sponsored by Daiichi Sankyo reveals at-risk patient groups and recent trends in disease management[1],[2] Not for US media Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced data from new sub-analyses of the ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - Jennifer Aniston Opens Up about Personal Experience with Dry Eye Symptoms, Which Have Been Reported by Nearly 30 Million Americans Jennifer Aniston is one of the millions of Americans who experience symptoms consistent with Chronic Dry Eye. Commonly referred to as Dry Eye, ...
Munich (ots/PRNewswire) - - ENSURE-AF results to be featured during a late-breaking clinical trial session - Five abstracts highlighting analyses from the global phase 3 ENGAGE AF-TIMI 48 study to be presented - Seven abstracts to reveal new findings from the PREFER in AF and VTE European patient registries Daiichi ...
Kanata, Ontario (ots/PRNewswire) - Agreement Highlights - Purchase agreement covers REVISS Services (UK) Ltd. and subsidiary REVISS Services Inc. (USA) - REVISS had ceased trading in cobalt-60 in April 2014 - REVISS Services will be integrated into the operations of Nordion (Canada) Inc. - Acquisition allows Nordion ...
London (ots/PRNewswire) - ViiV Healthcare today announced the start of a phase III programme to support regulatory filings for a two-drug regimen of dolutegravir (Tivicay®) and lamivudine (Epivir®) as a treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy. (Logo: ...
Stockholm (ots/PRNewswire) - Mr Costa, currently CEO of Nordic Nanovector ASA, a biotech company focused on the development of innovative treatments in hematology and oncology, brings to Oncopeptides more than 20 years' experience in the international pharmaceutical and biotech industry. Prior to his current position, he was Vice President of Europe, Middle East and Africa for Onyx Pharmaceuticals Inc. where he led the ...
Calgary, Alberta (ots/PRNewswire) - A data review by the independent Data Safety Monitoring Board resulted in a verbal recommendation for the BETonMACE trial to continue as planned without any modification. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that the independent Data and ...
Sunnyvale, California (ots/PRNewswire) - Next Generation Image-Guided Radiation Therapy Platform and Integrated Software Solutions are Now Available for Use by Clinicians in the European Union Accuray Incorporated (NASDAQ: ARAY) announced today that it has CE marked its Radixact(TM) Treatment Delivery System, Accuray Precision(TM) Treatment Planning System and iDMS(TM) Data Management System. The next generation hardware ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 - Merck is the first pharmaceutical company to collaborate with multiple diagnostic providers to support liquid biopsy RAS biomarker testing worldwide ...
Aberdeen, Scotland and Singapore (ots/PRNewswire) - Promising Read-Out for First-Ever Tau Aggregation Inhibitor to Enter Phase 3 Trials - LMTX® as monotherapy demonstrates significant reductions in disease progression in mild and moderate Alzheimer's disease - Strong results in both cognitive and functional tests supported by brain scan evidence of slow-down in progression of pathology - Study misses co-primary endpoints ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - The positive opinion is based on a pivotal Phase 3 study showing that ONIVYDE combined with chemotherapy significantly increased overall survival (OS) in patients with metastatic pancreatic cancer after previous gemcitabine based therapy Shire plc (LSE: SHP, NASDAQ: SHPG) today ...
Calgary, Alberta (ots/PRNewswire) - The commencement of this Phase 1 pharmacokinentic (PK) trial in patients with severe renal impairment is the first in a series of planned clinical trials designed with value creation in mind. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that dosing has commenced in a Phase 1 PK study with lead drug ...
Sunnyvale, California (ots/PRNewswire) - Accuray Incorporated (NASDAQ: ARAY) announced today preliminary results from a prospective, phase II trial evaluating once-daily accelerated partial breast irradiation (APBI) in patients treated with the TomoTherapy® System. The study, published in the June issue of the ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - HyQvia (Human Normal Immunoglobulin 10% and Recombinant Human Hyaluronidase) is the only subcutaneous IG treatment for primary and certain secondary immunodeficiencies that can be administered in one site, once a month (up to every four weeks) Shire plc (LSE: SHP, NASDAQ: SHPG) is launching a pediatric indication for HyQvia (Human ...
Düsseldorf (ots) - ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today announced the publication of data in the leading scientific journal Cell, demonstrating that such therapeutics can limit a variety of common human ...
London, England and Durban, South Africa (ots/PRNewswire) - ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy for Triumeq® (dolutegravir/abacavir/lamivudine) compared with atazanavir boosted with ritonavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) ...
Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of the investigational product Cladribine Tablets for the treatment of relapsing-remitting multiple ...
Melsungen/Johannesburg (ots) - On 30 June 2016, B. Braun Medical, the South African subsidiary of the German B. Braun Group, completed its acquisition of Dismed Pharmaceutical (Pty) Ltd and Dismed Criticare (Pty) Ltd, both out of business rescue. With over 600 employees in South Africa, B. Braun specialises in the ...
Takeda Pharmaceutical Company Limited
Osaka, Japan (ots/PRNewswire) - Takeda unveils new IBD Super Hero and graphic illustrations, developed in collaboration with Marvel Custom Solutions, to highlight the strength of and inspire confidence in those living with IBD If someone with inflammatory bowel disease (IBD) was a Super Hero, what would that hero ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - - An estimated 16 million people in the U.S. are diagnosed with dry eye disease - Xiidra is the first prescription eye drop FDA-approved to treat both the signs and symptoms of dry eye disease - U.S. launch of Xiidra planned for third quarter 2016 Shire plc (LSE: SHP, ...
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk announced today that data from 28 abstracts will be shared at the upcoming World Federation of Hemophilia World Congress (WFH) in Orlando, Florida, from 24-28 July. The WFH Congress is the largest ...
Toronto (ots/PRNewswire) - Last year, a randomized placebo-controlled pilot study using patented Vielight 810 Infrared (https://vielight.com/product/vielight-810/) and patent-pending Vielight Neuro (http://vielight.com/neuro-transcranial-intranasal-light/) wearable devices was conducted involving 19 patients affected by Alzheimer's disease or dementia. The findings ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - This press release is intended for a global audience. First therapy indicated in the EU for use in patients aged one year and above with SBS, a rare gastrointestinal condition Shire (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission has granted extension of ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media WCGC Abstract # 0-025; poster presentation, July 1, 2016, 10:35 am CEST - Phase III study shows response rate of 61.1% for patients treated with Erbitux plus FOLFOX - 31% decrease in risk of disease progression and 24% decrease in risk of ...
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma is a significant step closer to realising its vision of becoming the preferred dermatology care partner following a strategic partnership with AstraZeneca announced today. (Logo: http://photos.prnewswire.com/prnh/20130221/595427 ) The partnership covers potential new medicines for atopic dermatitis and psoriasis, two of ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - - Top-line SHP607 study results in extremely premature infants showed no impact on primary endpoint of reducing the severity of Retinopathy of Prematurity - Top-line analysis of secondary endpoints showed clinically relevant effects on severe complications related to lung and brain damage - These data support further ...
London (ots/PRNewswire) - Norgine B.V. today announced that it has completed the divestment of its MENA operations and product rights for MOVICOL®, MOVIPREP®, KLEAN-PREP® and NORMACOL® in MENA to Acino. (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) Peter Stein, CEO at Norgine said: "The divestment ...
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announces the European Medicines Agency (EMA) marketing approval of the mylife(TM) YpsoPump® insulin pump for use with prefilled pump ...